Background. Antibiotic administration to individuals with Shiga toxin-producing Escherichia coli (STEC) infection remains controversial. We assessed if antibiotic administration to individuals with STEC infection is associated with development of hemolytic uremic syndrome (HUS).
Shiga toxin-producing Escherichia coli (STEC) infections frequently prompt consideration of antibiotic treatment, prior to or after culture results are known. However, such treatment may increase the risk of developing hemolytic uremic syndrome (HUS). HUS consists of nonimmune hemolytic anemia, thrombocytopenia, and renal insufficiency and is believed to be caused by circulating Shiga toxins [1] . An association between antibiotic administration and HUS is plausible: in vitro, a variety of antibiotics increase Shiga toxin production by E. coli [2, 3] .
Two systematic reviews [4, 5] assessing HUS risk after antibiotic antibiotic administration to STEC-infected patients concluded that they neither decreased nor increased the likelihood of this complication. The first meta-analysis reported a pooled odds ratio (OR) of 1.15 (95% confidence interval [CI] , .79-1.68), but had methodological limitations. These include use of a fixed-effects model for data with a bimodal distribution, the treatment of studies with increased ORs as outliers [6] , and the heavy weighting given to a study in which 100% of patients who developed HUS and 99% of those who did not were given antibiotics [7] . The second described 19 studies but did not perform a meta-analysis. The inconclusive nature of these reviews has contributed to practice variation despite Centers for Disease Control and Prevention urgings against antibiotic use in these infections [8] . Nonetheless, approximately onethird of HUS patients in a 2007-2008 multicenter study of US and Scottish institutions [9] and in a nationwide survey of childhood HUS [10] received antibiotics prior to the development of HUS.
Given the ongoing administration of antibiotics to STECinfected individuals, the inconclusiveness of prior reviews, and recently published data, we conducted a meta-analysis to quantify the risk of developing HUS associated with antibiotic administration during the diarrheal phase of disease.
METHODS
We followed an a priori drafted protocol and published guidelines for conducting and reporting findings of systematic reviews and meta-analyses (MOOSE). Data sources and searches are provided in the Supplementary Text 1 and Supplementary  Table 1 .
Study Selection
Three trained study reviewers (J. X., M. S. N., W. L. H.) independently screened all identified publications for potential inclusion; those relevant by title and abstract were retrieved in full text. Eligible studies contained (1) a series of patients with documented STEC infection (confirmed by toxin assay, culture, or molecular techniques); (2) development of HUS; and (3) antibiotic administration prior to development of HUS (Table 1) . Studies were excluded if they (1) were reviews; (2) contained data that were reported more comprehensively in prior or subsequent reports; (3) provided insufficient information to determine the proportions who received/did not receive antibiotics and who developed/did not develop HUS; or if they described a series of cases in which (4) all participants received antibiotics or developed HUS or (5) antibiotics were administered after HUS developed.
Review processes and data extraction are described in the Supplementary Text 2.
Outcome Measures
The primary outcome was the development of HUS according to study definitions (Supplementary Table 3 ). Subanalyses were performed including only subjects meeting commonly used criteria for diagnosing HUS-namely, presence of microangiopathic hemolytic anemia, thrombocytopenia (ie, platelet count <150 000 cells/µL), and renal insufficiency defined as a creatinine level greater than the upper limit of normal for age [34] . [11] during a massive E. coli O157:H7 outbreak [28] . There were 37 cases of HUS, and each was considered to be culture positive caused by E. coli 0157:H7, and outbreak related. Dr Bell was contacted to provide the number of HUS cases that were culture positive, but the data were unavailable for review because of the time that has elapsed since the publication. Based on the following reasons, it was decided that the study and all cases should be considered as STEC positive: (1) E. coli O157:H7 was the overwhelming cause of HUS in Washington State in the 1980s and 1990s [29, 30] ; (2) inability to recover E. coli O157:H7 from a patient in Seattle with HUS is not uncommon if no antecedent stool culture is performed [29] ; (3) intense analysis of 37 children with HUS at a single pediatric hospital in Seattle, during the outbreak (and included in the report) reported by Bell et al, failed to identify an STEC pathogen in only 5 children [31] ; (4) endemic HUS and E. coli O157:H7 infections rarely occur in Washington State in January and February [18, 29, 30, 32, 33] . c Ikeda et al included in their study some cases of HUS in the absence of the identification of an STEC pathogen. However, this study was conducted during a massive localized E. coli outbreak, so the patients reported have been included in the summary estimates and analyses conducted [16] . d Composite measure is not available for clinical trials; itemized scores are provided in Supplementary Table 5 .
For all included studies, study definitions were extracted and compared with the aforementioned criteria.
Risk of Bias
The same reviewers independently (ie, blinded to other reviewers' scores) assessed the risk of bias (RoB) using the NewcastleOttawa scale (NOS) [35] , which assesses the quality and potential bias of nonrandomized studies in 3 domains: (1) cohort selection, (2) comparability, and (3) outcome assessment using 8 multiplechoice questions. However. reviewers were not blinded to study authors' identities. A study is deemed to be of good, fair, or poor quality if the score is ≥7, 6, and ≤5 (out of 9), respectively [36] . We used the Cochrane RoB (hereafter "RoB") tool to assess randomized trials. We used information pertaining to RoB to explore sources of heterogeneity. Two reviewers classified the quality of the body of evidence into categories (very low, low, moderate, high) according to domains of study limitations, inconsistency, indirectness, imprecision, and other considerations (eg, evidence of publication bias) using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology [37] .
Data Synthesis and Analysis
Evidence tables included design features, methodologic quality, study populations, sample size, settings, outcomes, and potential covariates. For each study, the raw data were extracted regarding antibiotic administration and occurrence of HUS as dichotomous variables. Two-by-two tables were constructed to enable calculation of crude ORs and 95% CIs. Pooled OR estimates and 95% CIs were obtained using random-effects models of Mantel and Haenszel. Evidence of statistical heterogeneity (I 2 test), reporting bias (Begg and Egger tests and funnel plot inspection), and publication bias (Duval and Tweedie trim-and-fill method) were also sought. Too few studies reported adjusted ORs, and the level of detail provided was inadequate to conduct preplanned analyses (eg, adjusting for white blood cell count). Consequently, studies reporting adjusted ORs were explored qualitatively. The following subanalyses were planned a priori: (1) children (ie, <18 years of age); (2) low RoB according to the NOS; (3) intermediate antibiotic use (ie, 25%-75% of patients received antibiotics); (4) moderate proportions developing HUS (ie, <20%); and (5) substantial numbers of subjects (ie, >100). Analyses were repeated when original reports included exposure data at varying time points (eg, antibiotics at 3 and 7 days after symptom onset); results were reported for both intervals only if there were significant differences. Additional analyses were performed at the request of peer reviewers. Two-sided P values were calculated with significance set at .05, using Review Manager (RevMan, Cochrane Collaboration), version 5.3.3.
RESULTS
We identified 2489 potentially relevant studies; 17 studies of 1896 infected individuals, of whom 349 (18.4%) developed HUS ( Figure 1; Table 1 ), met all criteria and were subsequently analyzed. Eight (47%) were retrospective cohort studies, 5 (29%) were prospective cohort studies, 3 (18%) were casecontrol studies, and 1 was a clinical trial. Sample sizes ranged from 11 to 304. Table 3 ). Thirteen required evidence of anemia and 14 required hemolysis. Ten and 3 studies employed platelet cut-points of <150 000 cells/µL and <100 000 cells/µL, respectively; 2 required "thrombocytopenia." A variety of definitions of renal impairment were employed, including elevated blood urea nitrogen (n = 2) or creatinine (n = 12) concentrations, "renal impairment/failure" without further definition (n = 2), and proteinuria and/or hematuria (n = 2). When the definitions of microangiopathic hemolytic anemia, thrombocytopenia, and serum creatinine level greater than the upper limit of normal for age are employed, 10 studies and 1309 subjects met eligibility criteria, and 7 studies and 587 subjects did not. Table 4 ). The funnel plot ( Supplementary Figure 2A ) was symmetric; there was no evidence of small sample bias from any tests performed (Begg, P = .71; Egger, P = .81). No studies were added by the trim-and-fill method.
Subgroup Analyses
Subanalyses using studies focusing on children or adults produced similar ORs ( Figure 12) . The median study RoB score was 6 (range, 5-9; Supplementary Table 5 ). The criterion that most studies failed to meet was "comparability," which requires that cases and controls be matched in the design and/or confounders adjusted for in the analysis.
When analysis was restricted to studies of low RoB (NOS score ≥7) the OR of developing HUS after antibiotic treatment increased to 1.95 (95% CI, 1.25-3.04; 6 studies; I 2 = 13%; Supplementary Figure 13 ). Heterogeneity was reduced and association between antibiotics and HUS increased when analyzing only studies with low RoB and that used a stringent HUS definition (OR, 2.24 [95% CI, 1.45-3.36]; 5 studies; I 2 = 0; Figure 3 ).
We repeated our quality assessment for this estimate and found it to be moderate (Supplementary Table 4 ; Supplementary Figure 1B) . A sensitivity analysis around the RoB assessment was performed by repeating the analysis including studies with NOS scores ≥6 and lowered the estimate of association to an OR of 1.58 (95% CI, .96-2.59; 10 studies), but the I 2 increased to 55%
(Supplementary Figure 14) . The ORs for infections caused by O157:H7 (OR, 1.44 [95% CI, .78-2.66]; 9 studies; I 2 = 61%) and non-O157:H7 (OR, [27] .
DISCUSSION
Antibiotic administration to individuals with STEC infection has remained a controversial topic for 2 decades, with reports claiming increased risk of [38] or protection from [16] HUS. Indeed, this risk was suggested in the first description linking STEC to HUS [39] . Controversy was furthered by a metaanalysis that reported no association between antibiotic administration and development of HUS [4] . When all identified studies are included in our meta-analysis, there is no definite association Figure 2 . Random-effects meta-analysis of studies comparing odds of developing hemolytic uremic syndrome (HUS) in patients with Escherichia coli infection treated with antibiotics compared to those who did not receive antibiotics. The term "favors no antibiotics" implies that when antibiotics were given to the patients with Shiga toxinproducing Escherichia coli (STEC) infection, we observed increased odds of developing HUS, and the term "favors antibiotics" implies that when antibiotics were given to the patients with STEC infection, we observed decreased odds of developing HUS. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel. Figure 3 . Random-effects meta-analysis of studies comparing odds of developing hemolytic uremic syndrome (HUS) including only studies deemed to be of low risk of bias and meeting HUS definition. The term "favors no antibiotics" implies that when antibiotics were given to the patients with Shiga toxin-producing Escherichia coli (STEC) infection, we observed increased odds of developing HUS, and the term "favors antibiotics" implies that when antibiotics were given to the patients with STEC infection, we observed decreased odds of developing HUS. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel. between antibiotic administration and the development of HUS. However, the nature of the association changes after a priori planned sources of heterogeneity are explored. Restricting the analysis to studies with low RoB and using the accepted HUS definition, the association strengthens (OR, 2.24 [95% CI, 1.45-3.36]) and the I 2 value becomes 0%, implying that this analysis reflects the true estimate of association. Since the publication of the first and only meta-analysis on this topic [4] , standards for conducting and reporting such studies have advanced. Although the pooled OR reported by Safdar et al (1.15 [95% CI, .79-1.68]) [4] is similar to what we found, they did not refine results by incorporating RoB or scrutinizing the definition of HUS employed. Also, in that study, data extraction from the Ikeda et al report [16] was problematic, as the protective effect of antibiotics (OR, 0.12 [95% CI, .02-.74]) reported is not readily reproducible [7] and appears to be based on the inclusion of a subgroup of patients from the original manuscript [40] .
Our meta-analysis benefited from a larger sample size (2245 vs 1121 infections) because of post-2002 publications. The prior analysis employed a fixed-effects model, which is inappropriate given the heterogeneity of included studies (I 2 not reported but P < .001), and it controlled for heterogeneity by removing 2 studies [19, 38] that strongly associated antibiotic administration and HUS; a pooled OR including them was not provided. Although our primary analysis found no significant association between antibiotic administration and HUS, its point estimate (OR, 1.33) leans toward an association, and the associations strengthened in all subsequent analyses. The studies included in the overall analysis are heterogeneous. Heterogeneity was eliminated by including only low-RoB studies and the generally accepted criteria for HUS (Figure 3 ). After applying more rigorous criteria (ie, low RoB and low RoB plus tight HUS definition), the point estimate further increased. These findings illustrate the importance of considering such elements in guiding future research.
Ideally an adjusted OR would be calculated, but this was not possible because of the lack of detailed reported by the individual studies. Of the 4 studies adjusting for illness severity, 3 found only small reductions in the measure of association and none found changes in direction or significance of findings. While clinical severity in individuals with bloody diarrhea might prompt antibiotic treatment prior to culture results, emerging nucleic acid amplification technologies could potentially identify etiologies of disease and influence care, thereby eliminating such ambiguity. This evolution in diagnostics highlights the importance of understanding the link between antibiotic administration and HUS, and our results will be helpful in response to rapid identification of infected individuals.
One major limitation of this analysis is that it is built on observational studies. The single randomized controlled trial included, which did not influence the results, was of limited utility because the treatment was provided late (day 7), which is close to the median day of onset of HUS in many North American series [9, 27] . We attempted to mitigate this weakness by addressing publication and selection biases and broadening our search criteria to identify all publications, even when antibiotic use and development of HUS was not the focus. We included non-English publications to increase the generalizability of our findings and both outbreak and sporadic infections to reduce the likelihood that different STEC clones, and their propensity to lead to HUS, would influence our findings.
Our work had additional strengths. The subanalyses we conducted reduced heterogeneity and strengthened the relationship between antibiotic use and HUS. We analyzed studies employing a stringent case definition of the outcome to hone in on key studies that accurately addressed the issue being evaluated while minimizing selection bias. This strategy excluded many potentially useful studies that did not include the data required to answer our research question. Most notably, data from the 2011 E. coli O104:H4 outbreak in Germany were not included as reports of antibiotic use included primarily patients with established HUS and asymptomatic/postsymptomatic carriers. Although neither of these groups were among our study's target population, we do believe that they provide evidence that treatment during HUS, or during convalescence, may not result in recurring HUS, or late HUS after symptoms have resolved [41] . By also not including the work of Carter et al [42] , who reported that antibiotic therapy early in illness was associated with increased fatalities, we might have understated our conclusions. Finally, data extractors were not blinded to our hypothesis, and 1 member of our team has previously published in the field [11, 27, 38] ; however, literature screening and data extraction were conducted independently by 3 individuals who had neither met, nor discussed manuscripts with the study's senior author (P. I. T.).
The intrinsic weakness and significant heterogeneity of the included studies, and their suboptimal designs, limit our ability to assign causality to antibiotic use. Although the lack of detail relating exposures to outcomes at a patient level limited some of our subanalyses, we did explore the relationships between country and acquisition (ie, outbreak vs sporadic). We additionally explored antibiotic class as a risk factor in our meta-analysis; no antibiotic/antibiotic class emerged as protective from the development of HUS, compared with nontreatment [25, 27] . Although there are intra-and interserotype differences in the release of Shiga toxin from STEC after exposure to antibiotics in vitro [43] , the decision to treat must be made at the time of initial presentation; hence, the variable release of toxin by an infecting strain cannot, for the foreseeable future, be entered into clinical decisions. Moreover, when O157:H7 is analyzed separately from non-O157:H7 strains, the OR CIs are overlapping.
In conclusion, after excluding studies at high RoB and those that did not employ an acceptable definition of HUS, there was a significant positive association between antibiotic administration and the risk of developing HUS. Given the lack of literature support for the value of early-in-illness antibiotics in STEC infections, and the potential for harm associated with their administration in such instances, these results can be used to promote a more unified public health recommendation against using antibiotics in individuals infected with STEC.
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